Skip to main navigation

Manage Cookie Consent

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

View preferences

Privacy and Cookie Notice {title} {title}

Home
About
Pipeline
Investors
Contact

News & Events

Company Overview
News & Events
- News Releases
- Events & Presentations
Stock Information
Financial Information
- SEC Filings
Corporate Governance
IR Resources
- Email Alerts
- Contact IR

News Category

Year

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

May 24, 2023

PDF Version

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 08, 2023

PDF Version

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

May 02, 2023

PDF Version

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Mar 21, 2023

PDF Version

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 08, 2023

PDF Version

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Mar 02, 2023

PDF Version

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Feb 22, 2023

PDF Version

Past Events

First Quarter 2023 Financial Results and Corporate Update Conference Call

May 9, 2023 at 8:30 AM EDT

Listen to webcast

2022 Business and Financial Update Conference Call

Mar 9, 2023 at 8:30 AM EST

Listen to webcast

Quoin Pharmaceuticals Ltd., Third Quarter Financial Results and Business Update Conference Call

Nov 10, 2022 at 10:00 AM EST

Listen to webcast

Second Quarter Financial Results and Business Update Conference Call

Aug 18, 2022 at 8:30 AM EDT

Listen to webcast

Presentations

Corporate Overview 1.4 MB

Subscribe

Sign up for alerts to stay up to date on Quoin Pharmaceuticals.

News:

May 24, 2023

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

May 08, 2023

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

2023 © Quoin Pharmaceuticals, Inc. Privacy Policy